-
1 month ago | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Andrew Blauvelt
Key takeaways: ESK-001, a tyrosine kinase 2 inhibitor, may be a promising new oral treatment for plaque psoriasis. Patients taking ESK-001 twice daily maintained skin clearance up to a year. ORLANDO — Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, according to a presentation at the American Academy of Dermatology Annual Meeting.
-
Nov 15, 2024 | 
tandfonline.com | Andrew Blauvelt |Hillel Cohen |Lena Lemke |Ines Brückmann
ABSTRACTBackground To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potential changes in immunogenicity.
-
Oct 10, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Andrew Blauvelt
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Among those treated twice daily with ESK-001 40 mg, 93% of patients reached PASI 75. Similarly, sPGA 0/1 was achieved by 76.1% of patients treated with twice-daily dosing in the same time frame.
-
Jul 31, 2024 | 
jamanetwork.com | Andrew Blauvelt |Blauvelt Consulting |Lake Oswego |Curdin Conrad
Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Control of Psoriasis Kilian Eyerich, MD; Khusru Asadullah, MD; Andreas Pinter, MD; Peter Weisenseel, MD; Kristian Reich, MD; Carle Paul, MD; Robert Sabat, MD; Kerstin Wolk, PhD; Stefanie Eyerich, PhD; Felix Lauffer, MD; Julianty Angsana, PhD; Friedemann J. H.
-
Jul 24, 2024 | 
jamanetwork.com | Andrew Blauvelt |Henrique D Teixeira |Eric Simpson |Antonio Costanzo
Error in Table Footnote Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, MD, MBA; Henrique D. Teixeira, PhD, MBA; Eric L. Simpson, MD, MCR; Antonio Costanzo, MD; Marjolein De Bruin-Weller, MD; Sebastien Barbarot, MD, PhD; Vimal H. Prajapati, MD; Peter Lio, MD; Xiaofei Hu, PhD; Tianshuang Wu, PhD; John Liu, MD, MS; Barry Ladizinski, MD, MPH, MBA; Alvina D.
-
Jul 17, 2024 | 
jamanetwork.com | Andrew Blauvelt |Emma Guttman-Yassky |Charles W. Lynde |Joel Schlessinger
Key PointsQuestion
Is cendakimab efficacious and safe in patients with moderate to severe atopic dermatitis (AD)? Findings
In this randomized clinical trial of 221 patients with moderate to severe AD, treatment with cendakimab was efficacious after 16 weeks, demonstrating improvements in skin clearance, pruritus, and the extent and severity of AD compared with placebo. Cendakimab was generally safe and well-tolerated.
-
Apr 8, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Andrew Blauvelt
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The adjudicated SIB rate with bimekizumab for psoriasis was in the same range as the general psoriasis population. The rate was also in the same range as those receiving anti-IL-17A and anti-IL-23 therapies.
-
Apr 8, 2024 | 
bpno.dk | Andrew Blauvelt
april 2024 In this MEDtalk, Dr. Andrew Blauvelt presents the best medications for psoriasis emerging, according to the Cochrane Group. The focus of the Cochrane review is the one-year efficacy in treating patients with moderate to severe plaque psoriasis without psoriatic arthritis.
-
Mar 7, 2024 | 
onlinelibrary.wiley.com | Bruce E. Strober |Andrew Blauvelt |Richard Warren |Kim A. Papp
INTRODUCTION The Janus kinase (JAK)-signal transducer and activator of transcription pathways play a major role in cytokine signalling in normal cellular processes and in immune-mediated diseases such as psoriasis.1, 2 JAK1,2,3 inhibitors are efficacious in patients with moderate-to-severe plaque psoriasis; however, JAK1,2,3 inhibitors are also associated with creatine phosphokinase (CPK) elevations, hyperlipidaemia and minimal hematologic abnormalities.3, 4 Therefore, it is important to...
-
Feb 14, 2024 | 
jamanetwork.com | Andrew Blauvelt |Henrique D Teixeira |Eric Simpson |Antonio Costanzo
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, MD, MBA; Henrique D. Teixeira, PhD, MBA; Eric L. Simpson, MD, MCR; Antonio Costanzo, MD; Marjolein De Bruin-Weller, MD; Sebastien Barbarot, MD, PhD; Vimal H.
